氢化可的松、维生素C与硫胺素联合治疗脓毒症与脓毒性休克:随机对照试验
本研究为单盲随机对照试验,纳入80例脓毒症患者,比较氢化可的松(50 mg每6小时一次,共7天)、维生素C(1.5 g每6小时一次,共4天)与硫胺素(200 mg每12小时一次,共4天)联合治疗与安慰剂(生理盐水)的疗效。主要终点28天全因死亡率在两组间无差异(27.5% vs 35%,P=0.47),但治疗组72小时序贯器官衰竭评估评分变化显著改善(P=0.02)。治疗组高钠血症发生更多(P=0.005)。预设亚组分析中,48小时内诊断为脓毒症的治疗亚组死亡率低于对照亚组(P=0.02)。研究在中期分析后终止。
要点
- 脓毒症或脓毒性休克患者中,氢化可的松+维生素C+硫胺素联合治疗较安慰剂未降低28天全因死亡率(27.5% vs 35%,P=0.47)。
- 联合治疗组72小时序贯器官衰竭评估评分变化较对照组显著改善(P=0.02)。
- 联合治疗组高钠血症发生例数多于对照组(P=0.005)。
- 预设亚组中,48小时内诊断为脓毒症的患者接受联合治疗者死亡率低于对照亚组(P=0.02)。
- 研究在中期分析后终止。
适用人群与场景
- 脓毒症或脓毒性休克患者。
处置流程与药物剂量
- 干预组:氢化可的松50 mg每6小时一次,共7天;维生素C 1.5 g每6小时一次,共4天;硫胺素200 mg每12小时一次,共4天。
- 对照组:安慰剂(生理盐水)。
研究设计与关键结果
- 单盲随机对照试验,80例患者随机分为联合治疗组(n=40)与生理盐水对照组(n=40),采用意向性分析。
- 主要终点28天全因死亡率:联合治疗组27.5% vs 对照组35%,P=0.47,无差异。
- 次要终点:联合治疗组72小时序贯器官衰竭评估评分变化较对照组显著改善(P=0.02)。
- 不良事件:联合治疗组高钠血症发生例数多于对照组(P=0.005)。
- 预设亚组分析:48小时内诊断为脓毒症的治疗亚组死亡率低于对照亚组(P=0.02)。
- 研究在中期分析后终止。
证据类型、等级与局限
- 证据类型:单盲随机对照试验。
- 研究在中期分析后终止。
对床旁实践的改变
- 在脓毒症或脓毒性休克患者中,氢化可的松、维生素C与硫胺素联合治疗未降低28天全因死亡率,不支持以降低死亡率为目的常规使用该联合方案。
- 使用该联合方案时需注意高钠血症发生例数增加。
- 48小时内诊断为脓毒症的患者亚组死亡率较低,但该结果为预设亚组分析,需进一步研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether hydrocortisone, vitamin C, and thiamine treatment can reduce the mortality of patients with sepsis is controversial.
RESEARCH QUESTION: To evaluate the efficacy and safety of hydrocortisone, vitamin C, and thiamine combination treatment for patients with sepsis or septic shock (HYVCTTSSS).
STUDY DESIGN AND METHODS: This single-blind, randomized controlled trial evaluated treatment with hydrocortisone (50 mg every 6 h for 7 days), vitamin C (1.5 g every 6 h for 4 days), and thiamine (200 mg every 12 h for 4 days) vs placebo (normal saline) in patients with sepsis. The intention-to-treat analysis was used. Primary outcome was 28-day all-cause mortality, and secondary outcomes were organ protection, procalcitonin reduction, and adverse events related to hydrocortisone, vitamin C, and thiamine.
RESULTS: Eighty patients were randomized to receive combination treatment (n = 40) or normal saline (n = 40). No difference in 28-day all-cause mortality was observed (27.5% vs 35%, respectively; P = .47); however, treatment was associated with a significant improvement of 72-h change in Sequential Organ Failure Assessment score (P = .02). In adverse events analysis, the treatment group exhibited more incidents of hypernatremia (P = .005). In prespecified subgroup analysis, patients of the treatment subgroup diagnosed with sepsis within 48 h showed lower mortality than those in the control subgroup (P = .02). The study was terminated after the midterm analysis.
INTERPRETATION: Among patients with sepsis or septic shock, the combination of hydrocortisone, vitamin C, and thiamine did not reduce mortality compared with placebo.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03258684; URL: www.clinicaltrials.gov.
参考来源
- Chang P, Liao Y, Guan J, et al. Combined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock: A Randomized Controlled Trial. Chest. 2020. PMID: 32243943. doi:10.1016/j.chest.2020.02.065
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。